Skip to main content

MRX-EAP An Expanded-Access Program for Maralixibat Patients with Cholestatic Pruritus Associated with Alagille Syndrome

NCT04530994

An Expanded-Access Program for Maralixibat Patients with Cholestatic Pruritus Associated with Alagille Syndrome

Associated Conditions

dermatology

Principal Investigator

Sponsor

Mirium Pharmaceuticals

The goal of this program is to provide access to maralixibat for the treatment of cholestatic pruritus associated with Alagille syndrome (ALGS), before the US Food and Drug Administration (FDA) approves maralixibat and it is available to you locally. Currently, there is no approved treatment for cholestatic pruritus associated with ALGS, and available medical approaches have limited treatment benefit.

This study is currently enrolling.